Efficacy of Personal Pharmacogenomic Testing as an Educational Tool in the Pharmacy Curriculum

NCT ID: NCT04889014

Last Updated: 2021-05-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

233 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-03

Study Completion Date

2021-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the use of personal genomic educational testing (PGET) on student knowledge and clinical skills surrounding pharmacogenomic testing to ensure it is of educational benefit to our student population. Students will be provided the opportunity to opt-in to test their own pharmacogenomic panel while participating in the standard curriculum. Students will have the option of using their own reports or dummy reports during classroom activities. Our hypothesis is that those students who have their own pharmacogenomics tested will show better overall performance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

We investigated the effect of PGET on student knowledge, comfort, and attitudes related to pharmacogenomics (PGx) in a non-blinded, randomized controlled trial. Consenting participants were randomized to receive PGET or no PGET (NPGET) during four subsequent years of a PGx course.
Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Investigators
Instructors and all study personnel were blinded to participant PGET assignment, PGx results, and survey results.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Personal genomic educational testing (PGET)

PGET group participants received their own pharmacogenomic testing results prior to the course modules covering material tested in the knowledge assessment

Group Type ACTIVE_COMPARATOR

Personal genomic educational testing (PGET)

Intervention Type GENETIC

PGET consisted of a panel of pharmacogenomic variants

No personal genomic educational testing (NPGET)

No PGET (NPGET) group participants did not receive their own pharmacogenomic testing results until after study completion.

Group Type PLACEBO_COMPARATOR

No personal genomic educational testing (NPGET)

Intervention Type GENETIC

Lack of pharmacogenomic testing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Personal genomic educational testing (PGET)

PGET consisted of a panel of pharmacogenomic variants

Intervention Type GENETIC

No personal genomic educational testing (NPGET)

Lack of pharmacogenomic testing

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willingness to provide informed consent for participation in the study
* Enrolled in 3rd year Doctor of Pharmacy course

Exclusion Criteria

* Unwilling or unable to provide consent for participation
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Arizona

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1602413309

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.